Pharmacy and Therapeutics (P&T) Medi-Cal Rx Transition Provider Bulletin - Pharmacy Updates P&T Formulary Updates DUR Board Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Oct 2021 Jun 2021 Mar 2021 Dec 2020 Sep 2020 Jun 2020 Mar 2020 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020 Sep 2020 Jun 2020 Mar 2020 November 2023 - 2023 Immunization Update: COVID-19, Influenza, RSV, HepB, Pneumococcal, HPV, Polio, Mpox, and MMR August 2023 - No Added Benefit from Concomitant Use of GLP-1 Agonists and DPP-4 Inhibitors June 2023 - Updated Guidance by the CDC and FDA for Prescribing Opioids June 2023 - FDA Approves First Over-the-Counter Naloxone Nasal Spray May 2023 - Clinical Review: Management of Acute Postpartum Pain January 2023 - Risks to Patients Exposed to Xylazine in Illicit Drugs January 2023 - Removal of DATA-Waiver (X-Waiver) Requirement January 2023 - Improving the Quality of Care: Treatment of Latent Tuberculosis Infection January 2023 - 2022 Immunization Update: Mpox, HepB, Influenza, COVID-19, Pneumococcal, Zoster May 2022 - Submitting Quality Data to the California Immunization Registry (CAIR2) Feb 2022 - Professional Organizations Push for Recall of Buprenorphine Dental Warning Dec 2021 - Improving the Quality of Care: Legislative Impact on the Use of Naloxone Sep 2021 - Immunization Updates Sep 2021 - Varenicline Apr 2021 - Potential Increased Arrhythmia Risk from Lamotrigine Jan 2021 - Recommendations for the Management of Acute Dental Pain Oct 2020 - Drug Safety Benzodiazepines Sep 2020 - Immunization Updates Aug 2020 - Clinical Review T2D May 2020 - Reproductive Health in Rheumatic and Musculoskeletal Diseases Apr 2020 - Withdrawal of All Ranitidine Products Apr 2020 - Update of Risks Associated with Use of Fluoroquinolones Mar 2020 - Mental Health Side Effects from Montelukast Archive » [ help with PDF files ] See more information designed specifically for health care providers.
